Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBO- CAN 2008. Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 2010. http://globocan.iarc.fr. Accessed August 3, 2011.
   Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–878.
   Web of Science ®Google Scholar
• van Grieken NC, Weiss MM, Meijer GA, et al. Helicobacter pylori- related and -non-related gastric cancers do not differ with respect to chromosomal aberrations. J Pathol. 2000;192(3):301–306.
   Web of Science ®Google Scholar
• Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopa- thology. 2011;58(3):383–394.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104(9):1372–1376.
   PubMed Web of Science ®Google Scholar
• Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986;77(5):1047–1052.
   PubMed Web of Science ®Google Scholar
• Kasprzyk PG, Song SU, Di Fiore PP, King CR. Therapy of an animal model of human gastric cancer using a combination of anti- erbB-2 monoclonal antibodies. Cancer Res. 1992;52(10):2771–2776.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol. 2005;27(3):681–685.
   PubMed Web of Science ®Google Scholar
• Gong SJ, Jin CJ, Rha SY, Chung HC. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 2004;214(2):215–224.
   PubMed Web of Science ®Google Scholar
• Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 1 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(Suppl 15):Abstr 4556.
   Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449.
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–748.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–462.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol. 2009; p. suppl;abstr 4515.
   Web of Science ®Google Scholar
• Kwon HC, Kim MC, Kim KH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol. 2010;6(4):278–285.
   Web of Science ®Google Scholar
• Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–2436.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal Adenocarcinoma: A FNCLCC and FFCD multicenter Phase III trial. J Clin Oncol. 2011;29(13):1715–1721.
   PubMed Web of Science ®Google Scholar
• Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–1737.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820.
   PubMed Web of Science ®Google Scholar
• Sasako M, Kinoshita T, Furukawa H, et al; for ACTS-GC group Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study). Ann Oncol. 2010;21(Suppl 8):viii225-viii49, Abst 709PD.
   Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–760.
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell. 2003;11(2):495–505.
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem. 1996;271(32):19029–19032.
   Web of Science ®Google Scholar
• Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem. 1999;274(13):8865–8874.
   PubMed Web of Science ®Google Scholar
• Hendriks BS, Orr G, Wells A, Wiley HS, Lauffenburger DA. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J Biol Chem. 2005;280(7):6157–6169.
   Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27(34):5838–5847.
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, et al. Humanization of an anti- p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285–4289.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008;32(1):89–95.
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(6):795–805.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immuno- reactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51(3):1034–1108.
   PubMed Web of Science ®Google Scholar
• Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series. Cell Oncol. 2010;32(1–2):57–65.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805.
   PubMed Web of Science ®Google Scholar
• Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immu- nohistochemical testing. Virchows Arch. 2010;457(3):299–307.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685–5692.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Doc- etaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Res. 2009;69(Suppl 24):Abstract 62.
   Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129–6134.
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–244.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–3685.
   PubMed Web of Science ®Google Scholar
• Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastu- zumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024–2031.
   PubMed Web of Science ®Google Scholar
• Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol. 2010;28(9):1473–1480.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–384.
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Vickery CW Quality of life in patients with cancers of the upper gastrointestinal tract. Expert Rev Anticancer Ther. 2001;1(2):269–276.
   PubMedGoogle Scholar
• Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium. Orlando, Florida, USA; 2010:Abst 7.
   Google Scholar
• Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11–16.
   PubMed Web of Science ®Google Scholar
• DeGramont A, Van Cutsem E, Tabernero J, et al. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol. 2011;29(Suppl 4):Abstr 362.
   Google Scholar
• Huang J, Sargent DJ, Mahoney MR, et al. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. J Clin Oncol. 2011;29(Suppl 4):Abstr 363.
   Google Scholar
• NCT01130337. A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer. 2010 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT01130337.
   Google Scholar
• RTOG-1010. Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer. 2010 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT01196390.
   Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastu- zumab therapy. J Clin Oncol. 2010;28(7):1138–1144.
   PubMed Web of Science ®Google Scholar
• Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215–1223.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.
   PubMed Web of Science ®Google Scholar
• NCT00829166. An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA). 2009 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00829166.
   Google Scholar
• NCT01120184. A Study of Trastuzumab-DM 1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). 2010 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT01120184.
   Google Scholar
• Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;28(2):171–179.
   Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743.
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011 Mar 17. [Epub ahead of print, doi:0.1093/annonc/mdr021].
   Web of Science ®Google Scholar
• NCT00486954. Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer. 2007 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00486954.
   Google Scholar
• NCT00680901. LOGiC – Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. 2008 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT00680901.
   Google Scholar
• Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol. 2010;28 (Suppl 15):Abstr 4057.
   Google Scholar
• Hecht J, Bang Y, Sobrero A, et al. A phase III study of CapeOx +/- lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. Eur J Cancer Suppl. 2009;7(2):385.
   Google Scholar
• Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008;7(7):1880–1889.
   PubMed Web of Science ®Google Scholar
• Campbell A, Reckamp KL, Camidge DR, et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol. 2010;28(Suppl 15):Abstr 7596.
   Web of Science ®Google Scholar
• NCT01152853. PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC). 2010 [cited 2011 13.4]; Available from: http://clinicaltrials.gov/ct2/show/NCT01152853.
   Google Scholar
• Swaby RF, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase 1/2 study. 2009 Breast Cancer Symposium. San Francisco, California, USA; 2009:Abstr 243.
   Google Scholar
• Hickinson DM, Klinowska T, Speake G, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010;16(4):1159–1169.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13(1):228–233.
   PubMed Web of Science ®Google Scholar
• Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985;3(6):818–826.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27(12):1999–2006.
   PubMed Web of Science ®Google Scholar
• Shimoyama R, Yasui H, Boku N, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12(4):206–211.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27(Suppl 15):Abstr 4540.
   Web of Science ®Google Scholar
• Cunningham D, Park S, Kang Y, et al. Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2011;29(Suppl 4):Abstr 6.
   Google Scholar
• Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010;16(5):1509–1519.
   PubMed Web of Science ®Google Scholar
• Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007;99(9):694–705.
   Google Scholar
• Janne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17(5):1131–1139.
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68(22):9221–9230.
   PubMed Web of Science ®Google Scholar
• Brachmann SM, Hofmann I, Schnell C, et al. Specific apoptosis induction by the dual PI3 K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009;106(52):22299–22304.
   PubMed Web of Science ®Google Scholar
• NCT01145404. Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (GastroLap). 2010 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01145404.
   Google Scholar
• NCT00526669. Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib. 2007 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT00526669.
   Google Scholar
• NCT01123473. Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer. 2010 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT01123473.
   Google Scholar
• NCT00838539. Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors. 2009 [cited 2011 13.4]. Available from: http://clinicaltrials.gov/ct2/show/NCT00838539.
   Google Scholar
• NCT01003158. Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. 2009 [cited 2011 13.4]. Available from: http://clinicaltrials. gov/ct2/show/NCT01003158.
   Google Scholar